|
1
|
Bray F, Ferlay J, Soeriomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
National Cancer Institute: Comprehensive
Cancer Information. https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-incidencia-de-cancer-no-brasil-2018.
Accessed June 29th, 2019.
|
|
3
|
Genetics Home Reference KRAS gene. US
National Library of Medicine. https://ghr.nlm.nih.gov/gene/KRAS.
Accessed June 30th, 2019.
|
|
4
|
Ciombor KK and Bekaii-Saab T: A
comprehensive review of sequencing and combination strategies of
targeted agents in metastatic colorectal cancer. Oncologist.
23:25–34. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai
SY, Ye QH, Yu Y, Xu B, Qin XY, et al: Randomized controlled trial
of cetuximab plus chemotherapy for patients with KRAS
wild-type unresectable colorectal liver-limited metastases. J Clin
Oncol. 31:1931–1938. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ishige T, Itoga S, Sato K, Kitamura K,
Nishimura M, Sawai S, Matsushita K, Suzuki K, Ota S, Miyauchi H, et
al: High-throughput screening of extended RAS mutations
based on high-resolution melting analysis for prediction of
anti-EGFR treatment efficacy in colorectal carcinoma. Clin Biochem.
47:340–343. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yokota T: Are KRAS/BRAF mutations potent
prognostic and/or predictive biomarkers in colorectal cancers?
Anticancer Agents Med Chem. 12:163–171. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tosi F, Magni E, Amatu A, Mauri G,
Bencardino K, Truini M, Veronese S, De Carlis L, Ferrari G,
Nichelatti M, et al: Effect of KRAS and BRAF
mutations on survival of metastatic colorectal cancer after liver
resection: A systematic review and meta-analysis. Clin Colorectal
Cancer. 16:e153–e163. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Brudvik KW, Kopetz SE, Li L, Conrad C,
Aloia TA and Vauthey JN: Meta-analysis of KRAS mutations and
survival after resection of colorectal liver metastases. Br J Surg.
102:1175–1183. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS
mutations in colorectal cancer. N Engl J Med. 369:1023–1034.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Venook A, Niedzwiecki D, Innocenti F, et
al: Impact of primary (1°) tumor location on overall survival (OS)
and progression-free survival (PFS) in patients (pts) with
metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405
(Alliance). J Clin Oncol. 34:3504. 2016. View Article : Google Scholar
|
|
12
|
Hutchison CA III: DNA sequencing: Bench to
bedside and beyond. Nucleic Acids Res. 35:6227–6237.
2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wojdacz TK, Dobrovic A and Hansen LL:
Methylation-sensitive high-resolution melting. Nat Protoc.
3:1903–1908. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Van Krieken JH, Rouleau E, Ligtenberg MJ,
Normanno N, Patterson SD and Jung A: RAS testing in metastatic
colorectal cancer: Advances in Europe. Virchows Arch. 468:383–396.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kothari N, Schell MJ, Teer JK, Yeatman T,
Shibata D and Kim R: Comparison of KRAS mutation analysis of
colorectal cancer samples by standard testing and next-generation
sequencing. J Clin Pathol. 67:764–767. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Neumann J1, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Simi L, Pratesi N, Vignoli M, Sestini R,
Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M and Orlando C:
High-resolution melting analysis for rapid detection of
KRAS, BRAF, and PIK3CA gene mutations in
colorectal cancer. Am J Clin Pathol. 130:247–253. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Er TK, Chang YS, Yeh KT, Chang TJ and
Chang JG: Comparison of two different screening methods for the
KRAS mutation in colorectal cancer. Clin Lab. 56:175–186.
2010.PubMed/NCBI
|
|
19
|
Karim B, Florence C, Kamel R, Nadia K,
Ines O, Raja M, Sarra BJ, Florent S and Amel BA: KRAS mutation
detection in Tunisian sporadic coloractal cancer patients with
direct sequencing, high resolution melting and denaturating high
performance liquid chromatography. Cancer Biomark. 8:331–340.
2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Negru S, Papadopoulou E, Apessos A,
Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S,
Aravantinos G, Ziras N, et al: KRAS, NRAS and
BRAF mutations in Greek and Romanian patients with
colorectal cancer: A cohort study. BMJ Open.
4(e004652)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mancini I, Santucci C, Sestini R, Simi L,
Pratesi N, Cianchi F, Valanzano R, Pinzani P and Orlando C: The use
of COLD-PCR and high-resolution melting analysis improves the limit
of detection of KRAS and BRAF mutations in colorectal
cancer. J Mol Diagn. 12:705–711. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Borràs E, Jurado I, Hernan I, Gamundi MJ,
Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M, et al:
Clinical pharmacogenomic testing of KRAS, BRAF and
EGFR mutations by high resolution melting analysis and
ultra-deep pyrosequencing. BMC Cancer. 11(406)2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Oati Ashtiani Z, Mehrsai AR, Pourmand MR
and Pourmand GR: High resolution melting analysis for raid
detection of PIK3CA gene mutations in bladder cancer. A
mutated target for cancer therapy. Urol. 15:26–31. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ma ES, Wong CL, Law FB, Chan WK and Siu D:
Detection of KRAS mutations in colorectal cancer by
high-resolution melting analysis. J Clin Pathol. 62:886–891.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Porcelli B, Frosi B, Terzuoli L, Arezzini
L, Pagani R, Civitelli S, Tanzini G, Orlando C, Pazzagli M,
Marziliano N, et al: Melting temperature analysis as quantitative
method for detection of point mutations. Clin Chem Lab Med.
39:501–504. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Karbalaie Niya MH, Basi A, Koochak A,
Safarnezhad Tameshkel F, Rakhshani N, Zamani F, Imanzade F, Rezvani
H, Adib Sereshki MM and Sohrabi MR: Sensitive melting analyses for
screening of KRAS and BRAF mutations in Iranian human metastatic
colorectal cancers. Asian Pac J Cancer Prev. 17:5147–5152.
2016.PubMed/NCBI View Article : Google Scholar
|
